Vincamine — time-proven efficacy and safety in treatment of patients with cerebrovascular diseases | Український Медичний Часопис

The increasing rate of population aging is a characteristic feature of the modern civilized world. This leads to an increase in the incidence of cardiovascular and cerebrovascular diseases, first of all coronary heart disease and stroke. According to the World Health Organization, they take the largest number of human lives. In particular in 2016, they accounted for 15.2 million deaths. Stroke is the second cause of premature death and increased disability of the population after coronary heart disease. The development and implementation in clinical practice drugs that prevent and restore the function of the damaged nervous system has been going on for a long time. Vincamine is one of the drugs used for several decades for treating various diseases of the brain. The article discusses its mechanism of action, the main chemical, pharmacological and clinical features.

References:

Adams H.P.Jr. (2009) Secondary prevention of atherothrombotic events after ischemic stroke. Mayo Clin. Proc., 84(1): 43–51. doi: 10.1016/S0025-6196(11)60807-0.
Albizzati M.G., Bassi S., Binda G., Passerini D. (1980) Effects of vincamine on EEG sleep patterns in man: a pilot study. Curr. Med. Res. Opin., 6(10): 653–657.
Bagoly E., Fehér G., Szapáry L. (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv. Hetil., 148(29): 1353–1358. doi: 10.1556/OH.2007.28115.
Chiu P.J., Tetzloff G., Ahn H.S., Sybertz E.J. (1988) Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am. J. Hypertens., 1(3 Pt. 1): 262–268. doi: 10.1093/ajh/1.3.262.
Debette S., Schilling S., Duperron M.G. et al. (2019) Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol., 76(1): 81–94. doi: 10.1001/jamaneurol.2018.3122.
Depresseux J.C. (1978) The effect of vincamine on the regional cerebral blood flow in man. Eur. Neurol., 17(2): 100–107.
Feigin V.L., Doronin B.M., Popova T.F. et al. (2001) Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol., 8(1): 81–85.
Go A.S., Mozaffarian D., Roger V.L. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics — 2013 update: a report from the American Heart Association. Circulation, 127(1): e6–e245. doi: 10.1161/CIR.0b013e31828124ad.
Gulyás B., Halldin C., Sóvágó J. et al. (2002) Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging, 29(8): 1031–1038. doi: 10.1007/s00259-002-0823-4.
Horváth S. (2001) The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion. Orv. Hetil., 142(8): 383–389.
Jeon K.I., Xu X., Aizawa T. et al. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA, 107(21): 9795–9800. doi: 10.1073/pnas.0914414107.
Jincai W., Tingfang D., Yongheng Z. et al. (2014) Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia. J. Clin. Neurosci., 21(4): 661–663. doi: 10.1016/j.jocn.2013.07.039.
Lin C., Chen F., Ye T. et al. (2014) A novel oral delivery system consisting in «drug-in cyclodextrin-in nanostructured lipid carriers» for poorly water-soluble drug: vinpocetine. Int. J. Pharm., 465(1–2): 90–96. doi: 10.1016/j.ijpharm.2014.02.013.
Medina A.E. (2010) Vinpocetine as a potent antiinflammatory agent. Proc. Natl. Acad. Sci. USA, 107(22): 9921–9922. doi: 10.1073/pnas.1005138107.
Medina A.E. (2011) Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front. Neurosci., 5: 21. doi: 10.3389/fnins.2011.00021.
Ning M., Zhou Y., Chen G., Mei X. (2011) Preparation and in vitro/in vivo evaluation of vinpocetine elementary osmotic pump system. Adv. Pharmacol. Sci., 2011: 385469. doi: 10.1155/2011/385469.
Olpe H.R., Steinmann M.W. (1982) The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons. J. Neural. Transm., 55(2): 101–109.
Sharma S., Deshmukh R. (2015) Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats. Neuroscience, 286: 393–403. doi: 10.1016/j.neuroscience.2014.12.008.
Sitges M., Galvan E., Nekrassov V. (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int., 46: 533–540.
Subhan Z., Hindmarch I. (1985) Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol., 28(5): 567–571. doi: 10.1007/bf00544068.
Szatmari S.Z., Whitehouse P.J. (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev., 1: CD003119.
Vitolo O.V., Sant’Angelo A., Costanzo V. et al. (2002) Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA, 99(20): 13217–13221. doi: 10.1073/pnas.172504199.
World Health Organization (2018) The top 10 causes of death (https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death/).
Zhang W., Huang Y., Li Y. et al. (2016) Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: a randomized, open-label, controlled, multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) trial. Clin. Drug Investig., 36(9): 697–704. doi: 10.1007/s40261-016-0415-x.